Oxaliplatin, a third-generation platinum compound with a 1,2-diaminocyclohexane (DACH) carrier ligand, is a recently developed agent with a broad spectrum of antineoplastic activities [1] . Hallmarks of this novel agent include its lack of crossresistance with cisplatin and carboplatin, synergistic activity with various other cytotoxic agents such as 5-fluorouracilleucovorin, and an excellent safety profile with a specific and manageable set of toxicities. When given alone or in combination with other cytotoxic drugs at its recommended dose of 85 mg/m 2 every two weeks or 130 mg/m 2 every three weeks, haematological side effects are commonly seen, but are generally mild. The most frequently encountered nonhaematological adverse events include gastrointestinal symptoms and a peripheral neurosensory toxicity (PNP), characterised by paresthesia and/or dysesthesia triggered or exacerbated by exposure to cold. This side effect, which is cumulative but reversible in most patients a few months after stopping treatment, does represent the principal dose-limiting toxicity in patients receiving oxaliplatin [1] .
Amifostine (WR-2721; ethyol) is a thiophosphate cytoprotectant agent with the potential to abrogate many chemotherapyinduced toxicities [2] , In preclinical studies, amifostine protected against the cytotoxic side effects of alkylating agents, platinum analogues, and radiation therapy in normal tissues, but preserved antineoplastic activity of these therapeutic modalities in tumour tissue. Most normal tissues were protected, including bone marrow, kidney, lung, and peripheral nerves. Usually amifostine is administered as a short intravenous (i.v.) infusion over 15 minutes. Recent pharmacokinetic studies, however, have shown acceptable plasma levels of its active metabolite (WR-1605) after subcutaneous (s.c.) injection [3] , and Koukourakis et al. have subsequently established feasibility, efficacy as well as a superior tolerance of this simplified administration schedule in a randomised phase II trial involving 140 patients with head and neck, thoracic, and pelvic cancers undergoing radical radiotherapy [4] .
In the present pilot study, we have investigated the therapeutic potential of an identical s.c. administration schedule of the cytoprotective agent amifostine to counteract oxaliplatinrelated PNP. Nine patients with metastatic colorectal cancer receiving chemotherapy with raltitrexed 3 mg/m 2 plus oxaliplatin 130 mg/m 2 every three weeks and six patients receiving irinotecan 175 mg/m 2 plus oxaliplatin 85 mg/m 2 both given i.v. on days 1 and 14 every four weeks were enrolled onto this study until today. All patients gave written informed consent according to institutional regulations. Their pretreatment characteristics are summarised in to assess the neurotoxicity occurring with oxaliplatin therapy taking into account both intensity and duration of the neurosensory symptoms [5] . After a median of three treatment courses (range 2-7) (median cumulative oxaliplatin dose 390 mg/m 2 , range 260-1020 mg/m 2 ) all of them had experienced oxaliplatin-related PNP ^ grade 2. Three patients had WHO grade 3, and twelve patients had grade 2 PNP. Twenty minutes prior to the next chemotherapeutic drug administration, patients were pretreated with amifostine 500 ing, diluted in 2.5 ml of normal saline, and given as a s.c. injection. In case of neurologic symptom relief, the subcutaneous amifostine regimen was to be maintained during subsequent courses.
One patient with grade 3 PNP had an immediate clinical benefit and experienced only mild paresthesia at cold exposition. Similarly, neurologic symptoms improved (by one WHO toxicity score) in nine patients with grade 2 PNP, including two patients after having undergone a second course of amifostine premedication. It seems noteworthy that neurologic symptom alleviation continued in all responding patients even with additional chemotherapy courses up to 8 (which was defined as the maximum treatment duration according to our protocol). Five patients did not respond; two of them initially presented with grade 3 PNP and three had grade 2 PNP. Apart from two patients with mild or moderate (WHO grade 1 or 2) nausea/ emesis, s.c. administration of amifostine did not cause any other adverse reactions. In agreement with a number of recent studies clearly showing that amifostine does not protect tumours from the cytotoxic activity of a variety of anticancer drugs, none of our patients progressed while receiving amifostine pretreatment. Overall, 8 of 15 (53%) patients had objective tumour responses lasting for a median duration of 8.8 months, and 5 exhibited stable disease for a median duration of 7.5 months; these data seem comparable with the therapeutic results obtained in previous patient series without amifostine pretreatment [6, 7] .
Our data suggest that amifostine 500 mg given as s.c. injection 20 minutes before oxaliplatin administration is able to counteract oxaliplatin-related PNP; in 10 of 15 patients enrolled in this pilot study, it effectively reduced the severity of this cumulative and dose-limiting side effect. Results were obtained without compromising the antitumour efficacy of the two chemotherapeutic drug regimens, and in agreement with previous reports, the s.c. route of administration was very well tolerated. Along with exploration of other specific medical interventions such as sodium channel blockers and anticonvulsants [8] , further investigations of the described promising new therapeutic option in a larger number of patients for a longer time period seems warranted, ideally in the form, of a placebocontrolled trial. 
